Taboola script Diabled on 7th April on request Adpushup head code Diabled on 7th April on request
HYDERABAD: The Centre is slated to purchase 30 crore COVID vaccine doses from Hyderabad based firm. In a statement released on Thursday, the Union Health Ministry has finalised arrangements with Hyderabad- based vaccine manufacturer Biological-E to reserve 30 crore of COVID-19 vaccine doses.
These vaccine doses will be manufactured and stockpiled by M/s Biological-E from August to December this year. An advance payment of Rs 1,500 crore was also made to M/s Biological-E.
The COVID-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trials after showing promising results in Phase-1 and 2 clinical trials and the vaccine is likely to be available in the next few months.
The proposal of the company was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for COVID-19, (NEGVAC).
The arrangement with M/s Biological-E is part of the wider endeavour of the Government of India to encourage indigenous vaccine manufacturers by providing them support in Research & Development (R&D) and also financial support,' the Ministry said.
Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 cr but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad.
#IndiaFightsCorona#LargestVaccineDrive
— Ministry of Health (@MoHFW_INDIA) June 3, 2021
🔴 Union Health Ministry finalises 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐚𝐫𝐫𝐚𝐧𝐠𝐞𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐌/𝐬 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥-𝐄 𝐋𝐭𝐝., 𝐇𝐲𝐝𝐞𝐫𝐚𝐛𝐚𝐝 𝐟𝐨𝐫 𝟑𝟎 𝐜𝐫 #COVID19Vaccine 𝐝𝐨𝐬𝐞𝐬.https://t.co/5hEKApgvTl @PMOIndia @drharshvardhan
Also Read: Serum Institute Seeks DGCI Permission To Manufacture Sputnik-V